Selecta Biosciences Inc Stock News

– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)-

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 42.86% and 49.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.

Selecta Biosciences (NASDAQ:SELB) is scheduled to announce Q4 earnings results on Thursday, Mar. 10, before market open.Consensus EPS estimate is -$0.08…

WATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR�

In last trading session, Selecta Biosciences Inc. (NASDAQ:SELB) saw 0.65 million shares changing hands with its beta currently measuring 1.20. Company’s recent per share price level of $1.91 trading at $0.05 or 2.69% at ring of the bell on the day assigns it a market valuation of $227.37M. That closing price of SELB’s stock is … Selecta Biosciences Inc. (NASDAQ:SELB) 14.14% Above Its 52-Week Low, How Long Will It Keep Rising? Read More »

WATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Companys Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11 th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

WATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ther

Selecta Biosciences Inc. (NASDAQ:SELB) concluded the trading at $3.33 on Wednesday, December 22 with a rise of 0.30% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.32 and 5Y monthly beta was reading 0.98 with its price kept floating in the Selecta Biosciences Inc. (SELB): Worth A Little Bit At $3.33 Read More »

4 penny stocks with bullish price targets & buy ratings from analysts. The post 4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117% appeared first on Penny Stocks to Buy, Picks, News and Infor

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

Selecta Biosciences, Inc. (NASDAQ:SELB) Director Timothy A. Springer purchased 211,190 shares of Selecta Biosciences stock in a transaction dated Wednesday, December 15th. The stock was bought at an average cost of $2.99 per share, with a total value of $631,458.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which []

Selecta Biosciences, Inc. (NASDAQ:SELB) CEO Carsten Brunn sold 17,196 shares of the stock in a transaction that occurred on Friday, December 10th. The shares were sold at an average price of $2.99, for a total transaction of $51,416.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this […]